ArticleActa parasitologica2025
Investigation of In Vitro and In Vivo Anti-leishmanial Activity of Auranofin on Leishmania Infantum.
Article in Acta parasitologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVisceral leishmaniasis (VL) is a serious health-threatening disease. Existing drugs are often toxic. So alternative treatments are constantly being considered and evaluated. This study aims to investigate Auranifin as potential new antileishmanial agent.
methodsThe fatality rate of different concentrations of auranofin (2, 4, 6, 8, 10, 12 μg/ml) on promastigote and amastigote forms after 24 h was calculated. The induction apoptosis in promastigotes by auranofin was also analyzed. Then, Leishmania-infected mice were treated with a concentration of 6.25 mg/kg and 12.5 mg/kg of Auranofin. After 1 month, the liver and spleen of the euthanized mice were separated, smears were prepared and pathology slides were prepared from the spleen and liver. Blood cell counts and liver and kidney enzymes were analyzed using heart blood. Histopathological examinations were performed on liver and spleen after treatment.
resultsThe fatality rate of auranofin at a concentration of 12 µg/ml on promastigote and amastigote forms of Leishmania infantum 24 h after culture was 99.35% and 94.05%, respectively. Over 90% of promastigotes and amastigotes were killed at concentrations of 8 µg/ml and 12 µg/ml of auranofin, respectively. Flow cytometry showed a high apoptosis rate (93.73%) at a concentration of 12 μg/ml. In the control group (without auranofin) 99% of cells were alive. Histopathological examination of the spleen and liver tissues showed a decrease in the degree of granulomatous and inflammatory changes in the groups treated with auranofin. Blood factors as well as Liver and kidney enzymes showed changes in both the test and control groups.
conclusionAuranofin has anti-leishmanial properties in both promastigotes and amastigotes, further studies are neecessary to explore this aspect.
Indexed as
Identifiers
40938476What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.